| Literature DB >> 31973703 |
Thomas M Elliott1, Xing J Lee2, Anna Foeglein3, Patrick N Harris4,5, Louisa G Gordon6,7,8.
Abstract
BACKGROUND: Hospital infection control requires timely detection and identification of organisms, and their antimicrobial susceptibility. We describe a hybrid modeling approach to evaluate whole genome sequencing of pathogens for improving clinical decisions during a 2017 hospital outbreak of OXA-181 carbapenemase-producing Escherichia coli and the associated economic effects.Entities:
Keywords: Agent-based model; Discrete-event model; Hospital outbreak; Pathogen sequencing; Simulation modeling; Whole genome sequencing
Mesh:
Substances:
Year: 2020 PMID: 31973703 PMCID: PMC6979342 DOI: 10.1186/s12879-019-4743-3
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Schematic of hybrid simulation model and information pathway used in this evaluation
Parameter description, values and sources used in the hybrid simulation model
| Parameter | Value | Source |
|---|---|---|
| Initialization | ||
| Initial starting population (n) | 551 | Hospital admissions dataset |
| Number of floors and wards | Level 5 (Ward A,B,C,D); Level 2 (Ward A,B,C,D,E); SIU; GARU (Bunya, Banksia, Cassia) | Building floor plans |
| Hospital Mechanics Sub Model | ||
| Population entry rate, patients per day | 24 | Calibration |
| Ward admission, transfers and stays a | see Additional file | Hospital admissions dataset |
| Susceptible-colonized sub model | ||
| Transmission parameter | Level 5 = 0.153, Level 2 = 0.14, SIU = 0.086, GARU = 0.086 | Calibration |
| Outbreak Management Sub Model | ||
| No WGS, outbreak number, patients with confirmed colonization | 7–15 | Expert opinion |
| No WGS, outbreak start delay, patients with confirmed colonization | 2–5 | Expert opinion |
| Microbiology test processing time, days | 2 | Expert opinion |
| Genome sequencing processing time, days (SD) b | 7 (0.5) | Expert opinion |
| Daily probability of patient being screened | Level 5 = 0.041, Level 2 = 0.043, GARU = 0.055, SIU = 0.056 | Calibration |
| Genome sequencing cost, AU$ (SD) c | 354.70 (53.2) | Clinical records |
| Microbiology test cost, AU$(SD) | 79.23 (11.88) | MBS item 69,306, PCR cost [ |
| Bedroom cleaning cost, AU$(SD) d | 70 (10.5) | Clinical staff |
| Bed closure, AU$ (Q1-Q3) | 216 (147–285) | Page et al., 2017 [ |
| Hourly wage for infection control nurse, AU$ (SD) | 40.33 (6.05) | Clinical staff & Queensland Health wage rates [ |
| Executive infection control meeting e, AU$ | 462.03 (69.3) | Clinical staff & Queensland Health wage rates [ |
| Increased virulence scenario | ||
| Infection chance | 0.165 | Tischendorf et al., 2016 |
| Time till infection | 27 days [ | Tischendorf et al., 2016 |
| Mortality (in-hospital) | 0.40 (0.5) | Chang et al., 2015 |
| Infection treatment costs, AU$ | $2650 | Chang et al., 2015 |
| End-of-life costs, AU$ | $19,696 | Reeve et al., 2018 |
| Environmental contamination scenario | ||
| ET odds-ratio for patients in contaminated beds | 2.65 | Mitchell et al., 2015 |
| Bed contamination length, days | 5–10 days | Kramer et al., 2006 |
GARU geriatric assessment and recovery unit, SIU spinal injury unit, SD standard deviation, PCR polymerase chain reaction, ET environmental transmission
aGamma distribution assigned
bNormal distribution assigned
cComprising: sample prep 15.00, sequencing 105.00, analysis/storage 18.00, scientist 102.50, isolate handling 5.00, labor admin 33.33 biostats 75.85
dHospital cleaning staff, labor hourly rate 31.24, curtains 33.00, consumables 5.00
e3 senior consultants 215.10, Infection control nurse 59.03, senior admin 65.10, manager 45.81
Model calibration: Parameter variation range, calibration formulae and results
| Parameter | Parameter calibration rangec | Optimal calibration results | Calibration #2 results | Calibration #3 results |
| Level 2 Beta valuea | 0.001–0.2 | 0.14 | 0.094 | 0.139 |
| Level 5 Beta valuea | 0.001–0.2 | 0.153 | 0.164 | 0.185 |
| SIU Beta valuea | 0.001–0.2 | 0.086 | 0.068 | 0.08 |
| GARU Beta valuea | 0.001–0.2 | 0.086 | 0.074 | 0.089 |
| Lvl5 microbial test prob.b | 0.01–0.07 | 0.041 | 0.055 | 0.04 |
| Lvl2 microbial test prob.b | 0.01–0.07 | 0.043 | 0.047 | 0.045 |
| SIU microbial test prob.b | 0.01–0.07 | 0.056 | 0.041 | 0.041 |
| GARU microbial test prob.b | 0.01–0.07 | 0.055 | 0.046 | 0.059 |
| RNG 1 Seed | 1–1000 | 701 | 457 | 952 |
| RNG 2 Seed | 1–1000 | 382 | 697 | 129 |
| RNG 3 Seed | 1–1000 | 465 | 810 | 348 |
| Detected colonizations | Actual outbreak | Optimal calibration | Calibration #2 | Calibration #3 |
Day 69: Lvl5, Lvl2, GARU, SIU | 6, 1, 1, 1 | 7, 3, 0, 1 | 8, 0, 0, 1 | 10, 1, 1, 1 |
Day 83: Lvl5, Lvl2, GARU, SIU | 11, 3, 1, 4 | 10, 6, 0, 1 | 16, 0, 1, 3 | 12, 1, 2, 1 |
Day 111: Lvl5, Lvl2, GARU, SIU | 25, 13, 14, 8 | 21, 10, 5, 8 | 23, 0, 11, 6 | 19, 4, 12, 1 |
| Total | 72 | 75 | 75 | 73 |
| Calibration Formulaed | abs (Lvl5 day69-AO Lvl5 day69) + abs (Lvl5 day83-AO Lvl5 day83) + abs (Lvl5 day111-AO Lvl5 day111) + abs (Lvl2 day69-AO Lvl2 day69) + abs (Lvl2 day83-AO Lvl2 day83) + abs (Lvl2 day111-AO Lvl2 day111) + abs (GARU day69-AO GARU day69) + abs (GARU day83-AO GARU day83) + abs(GARU day111-AO GARU day111) + abs(SIU day69-AO SIU day69) + abs(SIU day83-AO SIU day83) + abs(SIU day111-AO SIU day111) + abs(Total-AO Total) | |||
Lvl5 Level five, Lvl2 Level two, GARU Geriatric and Rehabilitation Unit, SIU Spinal injury unit, AO Actual outbreak, RNG random number generator, abs absolute value, prob Probability
aBeta value used in transmission formulae,
bThe daily probability a patient in that floor will be randomly screened
cThe values tested across 50,000 simulations
dDays 69 and 83 were chosen due spikes in colonization detections and day 111 was when the last detection occurred
Result summaries for the outcomes measures from 1000 probabilistic simulations for three best calibrations
| Total number of: | Optimal Calibration | Calibration #2 | Calibration #3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Calibrated Real life1 (Scenario 1) | No WGS (Scenario 2) | Early WGS (Scenario 3) | Calibrated Real life1 | No WGS | Early WGS | Calibrated Real life1 | No WGS | Early WGS | |
| Colonized patients (SD) | 197 | 352 (170) | 3 (0) | 136 | 219 (90) | 3 (0) | 137 | 448 (320) | 7 (9) |
| Detected patients (SD) | 75 | 152 (75) | 1 (0) | 75 | 118 (48) | 1 (0) | 73 | 217 (136) | 4 (7) |
| Sequencing tests (SD) | 79 | 2 (0) | 77 | 2 (0) | 74 | 4 (7) | |||
| Bed closures (SD) | 419 | 902 (486) | 11 (2) | 522 | 1145 (489) | 5 (1) | 428 | 1206 (767) | 19 (28) |
| Total costs $US (SD) | 318,654 (8406) | 531,109 (234,315) | 45,273 (3155) | 349,160 (8889) | 488,962 (178,224) | 45,637 (2005) | 322,981 (8441) | 705,474 (360,758) | 62,426 (38,507) |
| Whole genome sequencing costs | 19,469 (393) | 501 (51) | 18,975 (388) | 493 (10) | 18,221 (385) | 916 (1788) | |||
| Microbiology testing costs | 180,933 (7804) | 292,342 (110,451) | 40,397 (2775) | 193,338 (8169) | 303,916 (104,391) | 42,248 (1996) | 186,432 (7862) | 380,751 (160,304) | 54,187 (28,663) |
| Cleaning costs | 27,811 (1346) | 58,075 (31,402) | 733 (205) | 33,125 (1488) | 46,446 (20,638) | 233 (43) | 29,128 (1362) | 78,749 (49,321) | 1406 (1927) |
| Nursing costs | 3091 (183) | 6291 (3229) | 44 (8) | 3129 (184) | 4818 (2068) | 43 (2) | 3000 (179) | 8910 (5843) | 157 (302) |
| Infection control executive meetings costs | 24,366 (439) | 38,873 (20,044) | 1946 (124) | 22,133 (401) | 29,270 (12,413) | 1925 (34) | 21,803 (391) | 55,779 (35,168) | 2850 (2224) |
| Bed closure costs | 62,984 (2481) | 135,528 (72,750) | 1652 (372) | 78,460 (3012) | 104,511 (47,699) | 696 (104) | 64,397 (2523) | 181,286 (115,707) | 2911 (4131) |
NB: Empty cells denote where the outcome measures which were not modelled as part of the scenario
SD standard deviation, US United States, WGS whole genome sequencing
1No standard deviations were reported for non-cost outcome summaries in ‘Calibrated Real life’ as the model was calibrated using this scenario with a fixed outbreak signaling condition. Variation observed in ‘Calibrated Real life’ cost outcomes was due to the stochasticity of the cost parameters solely
Result summaries for the outcomes measures from 1000 probabilistic simulations for environmental and virulent scenarios
| Total number of: | Environmental contamination | Increased Virulence | ||
|---|---|---|---|---|
| No WGS | Early WGS | No WGS | Early WGS | |
| Colonized patients (SD) | 234 (179) | 2 (0) | 256 (157) | 3 (0) |
| Env contamination sites (SD) | 33 (28) | 0 (0) | ||
| Infected patients (SD) | 41 (25) | 1 (0) | ||
| Deaths (SD) | 6 (5) | 0 (0) | ||
| Detected patients (SD) | 123 (86) | 2 (0) | 119 (70) | 1 (0) |
| Sequencing tests (SD) | 4 (0) | 2 (0) | ||
| Bed closures (SD) | 720 (508) | 9 (1) | 692 (424) | 6 (2) |
| Total costs $US (SD) | 451,280 (252,232) | 44,994 (1954) | 606,367 (318,967) | 46,657 (2802) |
| Whole genome sequencing costs | 985 (20) | 502 (49) | ||
| Microbiology testing costs | 259,910 (119,687) | 40,141 (1950) | 268,621 (114,042) | 40,685 (2543) |
| Cleaning costs | 46,310 (32,867) | 476 (59) | 44,328 (27,333) | 370 (198) |
| Nursing costs | 4982 (3698) | 86 (5) | 4843 (3034) | 45 (9) |
| Infection control executive meetings costs | 31,802 (22,710) | 1925 (34) | 31,369 (18,619) | 1941 (101) |
| Bed closure costs | 108,277 (76,740) | 1381 (139) | 104,019 (63,868) | 915 (339) |
| Infection treatment costs | 74,828 (46,413) | 2200 (732) | ||
| Death costs | 78,359 (61,973) | 0 (0) | ||
NB: Empty cells denote where the outcome measures which were not modelled as part of the scenario
SD standard deviation, Env Environmental, US United States, WGS whole genome sequencing